HIV

EQS-News: Just – Evotec Biologics expands development and manufacturing agreement with ABL for broadly neutralising antibodies against HIV

Retrieved on: 
Wednesday, February 7, 2024

The new agreement builds on previous collaborations between Just – Evotec Biologics and ABL to design highly efficient manufacturing processes for broadly neutralising antibodies (“bNAbs”) against HIV.

Key Points: 
  • The new agreement builds on previous collaborations between Just – Evotec Biologics and ABL to design highly efficient manufacturing processes for broadly neutralising antibodies (“bNAbs”) against HIV.
  • Dr Matthias Evers, Chief Business Officer of Evotec, commented: “We are excited to expand our long-standing partnership with ABL to include the development of a third bNAb.
  • The development of safe and efficacious HIV-1 treatments and prevention strategies remains one of the highest priorities of the NIAID.
  • No financial details of the agreement between Just – Evotec Biologics and ABL were disclosed.

AHF Hammers Gilead Over Continued Profiteering

Retrieved on: 
Wednesday, February 7, 2024

AIDS Healthcare Foundation (AHF) continued its assault on Gilead Sciences in its ongoing advocacy campaign against the Bay Area drug maker over its voracious greed, patent manipulation, and obscene price hikes.

Key Points: 
  • AIDS Healthcare Foundation (AHF) continued its assault on Gilead Sciences in its ongoing advocacy campaign against the Bay Area drug maker over its voracious greed, patent manipulation, and obscene price hikes.
  • “Gilead continues to place profit above all else at the expense of patients’ access to its lifesaving drugs, including its latest and safest drug formulations,” says Michael Weinstein, AHF president and cofounder.
  • “From suppressing a safer formulation of one of its key HIV drugs to price gouging on its Hepatitis C medications, Gilead remains a company in search of a moral compass.
  • To learn more about AHF, visit us online at AIDShealth.org , find us on Facebook , follow us on Instagram , Twitter , and TikTok , and subscribe to our AHFter Hours podcast.

Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 6, 2024

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2023.
  • During the fourth quarter 2023, Gilead paid cash dividends of $943 million and utilized $150 million to repurchase common stock.
  • The Liver Disease portfolio sales were $691 million in the fourth quarter 2023 and remained flat compared to the same period in 2022.
  • Cell Therapy product sales increased 11% to $466 million in the fourth quarter 2023 compared to the same period in 2022.

ViiV Healthcare announces new packaging option now available in the U.S. for Dovato (dolutegravir/lamivudine)

Retrieved on: 
Tuesday, February 6, 2024

The sheets allow people living with HIV to view the number of pills left and track their doses.

Key Points: 
  • The sheets allow people living with HIV to view the number of pills left and track their doses.
  • The FDA approved the Dovato blister pack on November 3, 2023.
  • ViiV Healthcare plans to offer the Dovato blister pack in some European markets in 2024.
  • ViiV Healthcare will continue to offer Dovato in the 30-count pill bottle.

CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

Retrieved on: 
Thursday, February 1, 2024

The Company believes this submission will lead to the removal of the clinical hold currently in effect.

Key Points: 
  • The Company believes this submission will lead to the removal of the clinical hold currently in effect.
  • CytoDyn’s CEO, Dr. Jacob Lalezari stated, “Our HIV protocol has been revised and resubmitted following FDA input, and will study leronlimab in HIV patients who have increased inflammation and immune activation, which causes heart attacks, strokes, and other vascular events.
  • Glioblastoma is a common and often untreatable form of primary brain cancer.
  • CytoDyn is fortunate to be able to evaluate the potential effects of leronlimab in a pre-clinical model of this all too often deadly cancer.”

Trinity Biotech Announces Q3 2023 Financial Results & Business Update

Retrieved on: 
Wednesday, January 31, 2024

DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) today announced the Company’s results for the quarter ended September 30, 2023.

Key Points: 
  • DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) today announced the Company’s results for the quarter ended September 30, 2023.
  • In our HIV business, shipments of Uni-Gold are expected to be lower than Q3, 2023 due to the typical irregular quarter on quarter ordering patterns in that business.
  • At June 30, 2023 and September 30, 2023, the assets and liabilities attributable to Fitzgerald Industries have been de-recognised from the Consolidated Balance Sheet.
  • Total revenues for Q3, 2023 were $14.7 million which compares to $15.7 million in Q3, 2022, a decrease of 6.5% and which were broken down as follows:

Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc.

Retrieved on: 
Wednesday, January 31, 2024

DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced it has entered into a definitive agreement to acquire the biosensor and Continuous Glucose Monitoring (“CGM”) assets of privately held Waveform Technologies, Inc. (“Waveform”) for $12.5 million in cash, 9 million American Depositary Shares (“ADSs”) of the Company and additional contingent consideration.

Key Points: 
  • Waveform will no longer sell the Cascade device and the Company will not sell that device in its current form.
  • The remaining $9.5 million is available for general corporate purposes including for the further development of the CGM and biosensor technologies.
  • Waveform is part of a portfolio company of Perceptive and the 9 million ADS being issued by the Company as partial consideration for the acquisition of the Waveform assets will be issued to Perceptive.
  • The Company will host a conference call on Wednesday, January 31 at 8:30 a.m. EST to discuss its recent Waveform acquisition.

Global Research Antibodies Market Report 2024, Featuring Profiles of Abcam, Thermo Fisher Scientific, Cell Signaling Technology, Merck, Sino Biological & Bio-Rad - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 31, 2024

The global market for research antibodies was valued at approximately $3.5 billion in 2022.

Key Points: 
  • The global market for research antibodies was valued at approximately $3.5 billion in 2022.
  • Among product segments, the primary antibody segment accounted for the highest market share in the global market for research antibodies in 2022.
  • The advancement of biological discoveries will result in the need for more molecular targets to be detected by their antibodies.
  • This report segments the global market for research antibodies based on type of antibody, clonality, host, major reactivities, application, end user and region.

Uvax Bio Announces Dosing of First Participant in Phase 1 Clinical Trial Evaluating Two Vaccines to Prevent HIV-1 Infection

Retrieved on: 
Tuesday, January 30, 2024

“UVAX-1107 and UVAX-1197 represent an advancement in HIV vaccine technology with industry-recognized innovations in our antigen design and delivery.

Key Points: 
  • “UVAX-1107 and UVAX-1197 represent an advancement in HIV vaccine technology with industry-recognized innovations in our antigen design and delivery.
  • Uvax Bio expects to report topline data from the Phase 1 trial in the fourth quarter of 2024.
  • The novel protein nanoparticle vaccine candidates are designed for active immunization and are intended to prevent HIV-1 infection.
  • Furthermore, preliminary screening assays demonstrated appreciable neutralization in serum when tested against a panel of primary HIV-1 isolates.

AvitaCare Atlanta and MedCura Health Encourage Atlantans to "Be Fearless," Learn Their HIV and STI Status

Retrieved on: 
Wednesday, January 31, 2024

ATLANTA, Jan. 31, 2024 /PRNewswire/ -- AvitaCare Atlanta and MedCura Health are partnering to bring Atlantans a weeklong testing event for human immunodeficiency virus (HIV) and sexually transmitted infections (STIs) from February 5-11, 2024, at AvitaCare Atlanta's clinic located at 2140 Peachtree Road, Ste. 232, between Midtown and Buckhead.

Key Points: 
  • According to the U.S. Centers for Disease Control and Prevention (CDC), 16 percent of Georgians with HIV are unaware of their status, which means they aren't getting the HIV care they need.
  • "There's no power in the unknown, only fear," says AvitaCare Atlanta Medical Director Quintin R. Robinson, MD, AAHIVS.
  • "People living with HIV or diagnosed with an STI can enjoy full, healthy lives with treatment.
  • "Testing is crucial to helping the Atlanta community put an end to these historic health disparities."